Current methods for measuring the ef®ciency of splicing in mammalian cells rely on either direct analysis of the RNA, which does not lend itself to rapid assays, or on single reporter functions that are subject to numerous intrinsic variables. If two protein activities are encoded within a single reading frame but on separate exons, with an intervening sequence containing termination codons, then the expression of the second activity is dependent on removal of the intervening sequence by pre-mRNA splicing. Thus, the ratio of the activities encoded by exon 2 to exon 1 re¯ects the ratio of expression from spliced mRNA to the total expression of spliced and unspliced RNA. This provides a rapid and convenient assay for the effects on splicing ef®ciency of trans-acting factors or of alterations in the sequences of the intron and surrounding exon sequences.
INTRODUCTION
The splicing of mammalian pre-mRNA is complex in terms of both the signals that affect it and the number of factors involved in the reactions. Apart from the consensus sequences around the splice junctions, sequences at relatively distant sites within the exons and the introns are important in determining not just the ef®ciency of the reactions but also the sites of splicing. Understanding the roles of these sequences is important because the consensus sequences do not suf®ce to specify the correct sites; there are many additional sites that appear to satisfy the basic requirements and yet are not used. In addition, approximately one-half of all human genes encoding proteins appear to produce several isoforms of mRNA and protein by alternative splicing, often in a regulated way, but very few of the sequences that control the availability and level of use of the alternative sites have been identi®ed yet.
The identi®cation of factors that affect mammalian splicing is generally done by transfection of fragments of a gene into mammalian cells, followed by analysis of sequences included in the mRNA expressed. However, it is not usual for the ef®ciency of splicing of an intron to be measured directly. In most cases, the assay is based upon the examination of mature mRNA and addresses the mechanisms by which one site is selected rather than another. Thus, for example, preferences among candidate 5¢ splice sites or 3¢ splice sites are tested by the use of competing alternative sites (1±5) and the sequences that affect the use of an exon are tested by measuring the levels of mRNA in which the exon is included or excluded (skipped). This method has the advantage that many of the other factors that might affect expression, such as variations in transfection ef®ciency or transcription, are eliminated, while differences in stability of the various forms of mRNA cannot be ignored (2) but can be assumed to be less than might be expected between spliced and unspliced RNA. There are two major disadvantages to such strategies: there is no information bearing directly on the ef®ciency of splicing, and the direct analysis of mRNA by RT±PCR, RNase protection or northern blotting is relatively laborious and does not lend itself to high throughput analyses. Reporter assays have been used in several cases, but these have been single reporter functions (6, 7) , in which activity depends on splicing to remove an intron or incorporate an exon, and they are susceptible to variation between samples in the levels of transfection, transcription, etc.
Inferences drawn on the basis of competition between alternative splicing pathways can be misleading. For example, the numerous studies using RT±PCR to analyse incorporation or skipping of an exon after mutagenesis of local sequences are very readily interpreted in terms of exon de®nition, a widespread and important phenomenon that is of considerable value in understanding splice site usage, but they may not reveal cases in which one of the¯anking introns has been spliced, simply because partially spliced RNA is less likely to be detected proportionately.
The most common alternative strategy for identi®cation of factors that affect splicing ef®ciency is by the analysis of splicing in vitro, in a nuclear extract. This is a powerful and important method that has been used widely. However, it has several limitations: it requires the use of relatively short transcripts that usually lack the complexity and length of the natural pre-mRNA, and thus may not identify the rate-limiting steps for expression in vivo; it is dif®cult to test a wide range of protein factors because of the labour required to prepare these proteins (many of which, in the case of splicing factors, are not readily prepared in soluble or native form); and there are very few examples of active splicing extracts that have been made from differentiated cells, i.e. it is not a useful route in most *To whom correspondence should be addressed. Tel: +44 116 2523482; Fax: +44 116 2523369; Email: eci@leicester.ac.uk cases for identifying sequences that affect tissue-speci®c splicing.
In contrast to the situation in mammalian cells, it is normal to analyse splicing ef®ciency as such in yeast. This is generally done by direct analysis of the mRNA and unspliced RNA, often by primer extension without ampli®cation. A more rapid screen is possible with a reporter assay, again based on successful expression of a protein after splicing. A particularly good example is CUP1, in which activity can be measured as the copper resistance of growth and correlates very well with splicing ef®ciency (3). Many of the variables that affect transient expression assays in mammals are eliminated because stable and well-characterised clones are used.
To develop a simple and reliable assay for splicing ef®ciency, rather than competition, in mammals, a reporter activity that depends on splicing should be linked to a second activity that corrects for variations in either transfection ef®ciency or any other steps in transcription and processing. Ideally, the second activity would report the level of unspliced RNA. For this purpose, we have devised a reporter construct in which splicing produces one signal (luciferase activity) but both unspliced and spliced RNA produce b-galactosidase activity. Thus, the ratio of the two activities can be used as a rapid screen to detect mutations or trans-acting factors that might affect the ef®ciency of pre-mRNA splicing.
MATERIALS AND METHODS

Plasmid construction
The bifunctional reporter plasmid was based upon pBLUGA (8) , which contains reading frames for b-galactosidase and luciferase, separated by a termination codon (to assay selenocysteine incorporation) in between SalI and BamHI sites. An exon±intron±exon unit was cloned into these sites. In the case of plasmid pTN23, the exon and intron comprised nucleotides 6084 ±6237 and 7026 ±7095 of Ad2, with a novel 5¢ splice site at 6171/72 (9), which were joined to nucleotides ±5 to +76 of exon 6 of the skeletal muscle-speci®c mRNA isoform of human as-tropomyosin gene TPM3. Plasmid pTN24 contained an additional 25 nt from the tropomyosin intron, i.e. nucleotides ±30 to +76 of TPM3 exon 6. Exonic (Ex mut) and intronic (In mut) mutations were obtained by site-directed mutagenesis where the (GGA) 3 repeat and the nucleotides ±9 to ±26 of exon 6 were randomly replaced. For in vitro splicing assays, the same Ad2/TPM3 sequences were transcribed, but the adenovirus sequence began at nucleotide 6023 and included a natural 5¢ splice site at 6079/80 (TN23 ww and TN24 ww ). Complete reading frames for human Tra2b (Ayres et al., manuscript in preparation), Tra2a, hnRNPG-T and RBMY (Nasim et al., data not shown) were cloned in pEGFP-C1 and pECFP-N1 (Clontech) in frame with thē uorescent protein. Human hnRNPG was cloned in pCG10 vector (10) .
Gene transfer, cell culture and enzymatic assay HEK-293 (human embryonic kidney) cells were transiently transfected with relevant plasmids using Gene Jammer (Stratagene). Cells were harvested 48 h after transfection (11) , and b-galactosidase and luciferase activities were measured using Dual Light â System (Biosystems).
Reverse transcription±polymerase chain reaction (RT±PCR)
Total RNA was isolated using TRIreagent (Helena Biosciences). Any contaminating DNA was removed by treatment with restriction endonuclease and DNase, extraction with solvent and ethanol precipitation. After reverse transcription, PCR was done with Extensor Ready mix 1 (ABgene) and primers directed to the b-galactosidase and luciferase sequences for 18, 22 and 26 cycles. One of the primers was labelled with [g-32 P]ATP, so for analysis the products were run onto a denaturing gel and quanti®ed with a PhosphorImager. RNA processing assay in cell free system Conventional in vitro transcription and splicing reactions were carried out (12) and the splicing products were analysed on a polyacrylamide gel.
RESULTS
The general principle of the method we have adopted is shown in Figure 1 . The reporter system used in this work is based on the genes encoding b-galactosidase and luciferase, which are highly sensitive and linear across several orders of magnitude. We have constructed a set of reporter constructs where these two reporter genes were fused with a recombinant fragment containing two exons and a single intron (Fig. 1A) . Upon transfection of these reporter plasmids into a mammalian cell line, transcription from the SV40 promoter would produce a pre-mRNA, which contains three translation stop signals in the intron. This pre-mRNA could be processed in either of two ways. If it is not spliced, the mRNA would contain multiple translation stop signals in the intron. Translation termination would result in the production of the b-galactosidase protein alone. In the event of splicing, the internal stop signals would be removed and a b-galactosidase±luciferase fusion protein would result. Since the luciferase activity would be produced only after splicing, whereas b-galactosidase would be expressed by spliced and unspliced mRNA, the ratio of b-galactosidase and luciferase activities should indicate the proportion of cytoplasmic mRNA that is spliced. Complete splicing would give the highest ratio of luciferase to b-galactosidase. It might be expected that spliced and unspliced RNA would be polyadenylated, exported and degraded with different ef®ciencies, but the same limitation applies to the analysis of splicing by any other method.
To test whether the assay worked, HEK-293 cells were transfected with a plasmid (pTN23) that contained an adenovirus 2 sequence as the 5¢ exon and intron, and an alternatively spliced exon from tropomyosin as the 3¢ exon. A second plasmid was identical but for the inclusion of 30 nt from the intron preceding the exon in tropomyosin (pTN24). The cells were harvested 48 h after transfection. Analysis by western blotting of cells transfected by pTN23 showed that a protein of a size appropriate for the fusion protein had been made (Fig. 1B) . Measurement of the b-galactosidase and luciferase activities showed that the luc/gal ratio in cells transfected with pTN23 plasmid was signi®cantly higher than that from cells transfected with pTN24 ( Fig. 2A ; all values are means from 6 to 12 independent transfections). Mutations in the exon and intron sequences resulted in signi®cant changes in the luc/gal ratio, suggesting that there had been effects on the splicing ef®ciency.
The sensitivity of the assay to trans-acting modulators of splicing ef®ciency was assayed by co-transfection with plasmids encoding Tra2a, Tra2b, hnRNP G, hnRNP G-T and RBMY. These produced marked changes in the luc/gal ratio. We have also transfected the plasmids pTN23 and pTN24 in C2C12 (mouse myoblast cell line, ATCC number CRL-1772) and NT2 precursor (human teratocarcinoma cell line, Stratagene) cell lines. The results were similar to those obtained in HEK-293 cells (data not shown).
To con®rm that the luc/gal ratio was correlated with the proportion of spliced mRNA, the experiments were repeated and the RNA analysed by RT±PCR (Fig. 2B) . The bands corresponding to spliced and unspliced RNA were quanti®ed to measure the apparent proportion of spliced RNA (Fig. 2C) . Strikingly, the results from analysis by RT±PCR agreed well with the results obtained using the reporter activities (Fig. 2D ). There were parallel changes in the apparent level of splicing by both assays when the substrate was mutated or potential modulating factors were co-transfected. Thus, the absence of some or all of the 30 nt portion of tropomyosin intron in pTN23 and In mut enhanced the proportion of spliced mRNA, whereas an exon mutation reduced it considerably. Similarly, the two Tra2 proteins seemed to stimulate splicing, and the hnRNP G family proteins to reduce it, hnRNP G being most effective. We conclude that the conventional assay of mRNA splicing by RT±PCR validates the reporter assay and that the effects of mutation and trans-acting factors on the proportion of spliced mRNA can be ranked in effectiveness by this assay.
To con®rm that the changes in the proportion of spliced RNA inferred from the RT±PCR and reporter assays were produced by changes in splicing ef®ciency, transcripts containing the adenovirus and tropomyosin portions of pTN23 and pTN24 were tested in standard in vitro splicing reactions. The transcripts contained an additional 60 nt of adenovirus sequence at the 5¢ end, which included an alternative 5¢ splice site. As with the results from both in vivo assays, it can be seen in Figure 3 that the tropomyosin intron sequence in TN24 inhibited splicing very substantially, particularly the second step. Compared with TN23, there was almost no mRNA, and the intermediates accumulated slightly.
DISCUSSION
The disadvantages of conventional methods for assaying splicing ef®ciency in mammalian systems prompted us to develop a method based on the use of an indirect reporter system that bypassed a number of the variables that affect single reporter assays. This system comprises two signals, derived from the translation of both spliced and unspliced RNA in mammalian cells. Upon splicing the internal translation stop signals are removed, which leads to the production of a b-galactosidase±luciferase (gal±luc) fusion protein (Fig. 1B) . Without splicing, expression of b-galatosidase occurs but translation termination in the intron prevents the production of luciferase. We have tested the dual-reporter assay in several ways to show that it re¯ects the ef®ciency of splicing. The highest ratio of luciferase/galactosidase activity was observed when the intron was removed (data not shown), and luciferase activity was completely abolished when the 5¢ splice site was mutated (data not shown). Using conditions or mutations that are known to affect the ef®ciency of splicing, we found that there is a good correlation between the level of splicing determined by RT±PCR and the luciferase/galactosidase ratio (Fig. 2D) .
There are several respects in which it was surprising that such a straightforward assay worked well. The ®rst is that unspliced RNA tends to be retained in the nucleus (13) . This is a dif®culty that affects any attempt to measure the ef®ciency of splicing based on measurements of pre-mRNA levels, because the stability of retained RNA is likely to be different from that of exported RNA. One solution, although it does not lend itself to high throughput-type assays, is to measure the level of pre-mRNA for one intron compared with that of another intron in the same gene (14) . However, previous investigations (13) and our own results indicate that some unspliced pre-mRNA is exported and translated, and our results suggest that the fraction of unspliced RNA exported might not change with changes in the ef®ciency of splicing. It is likely that some trans-acting factors or cis-elements being assayed might affect export, and this should be considered when interpreting any apparent increases in splicing ef®ciency.
Another potential complication envisaged was that the presence of translation termination codons in the pre-mRNA might compromise it. However, nonsense mediated decay (NMD) requires splicing (15) ; in the reporter assay we describe, the spliced mRNA has no premature termination codons, whereas the mRNA that does contain premature termination codons is, by de®nition, unspliced. There was no evidence of NMD from experiments (8, 11 ) that investigated selenocysteine incorporation.
Apart from an increase in the proportion of spliced RNA or a decrease in pre-mRNA export, there are other routes by which the luciferase/galactosidase ratio might be increased which need to be borne in mind when appraising the results. For example, the ratio observed for pTN23 was increased dramatically (47-fold, data not shown), beyond that seen with the intron-less constructs, upon co-transfection with SRrp40 (TASR-2) (16,17). Investigation showed that the level of galactosidase activity was depressed in this case because a cryptic upstream 5¢ splice site had been activated by SRrp40. Such instances are unlikely to signi®cantly affect the usefulness of the method, as long as a second method is used to validate the most interesting candidates that emerge from a wide initial screen. In addition, it is possible to remove cryptic sites from any substrate of interest by mutagenesis.
This method is very convenient for a rapid screen with a panel of chemicals or co-transfected cDNA. However, a screen for positively acting factors should be done with introns that do not splice with high intrinsic ef®ciency. For example, a screen of SR proteins with pTN23 showed only modest improvements in the ef®ciency of splicing (not shown) because the level was high initially (Fig. 2B) . It is possible that all assays based upon the analysis of spliced and unspliced or alternative mRNA in vivo might underestimate the effects of positive trans-acting factors. Even when 100% of the mRNA has been spliced, such factors could further increase the rate of splicing and thus reduce the losses of pre-mRNA to degradation in the nucleus. This would be manifest only as an increased level of mRNA.
This method would be useful to screen chemical libraries to identify drugs that affect speci®c splicing reactions. In this case it would be advantageous to set up stable incorporation of the bi-functional reporter into a mammalian cell line. This would allow screening for chemicals that would rescue or suppress particular splicing reactions in cases where there would be therapeutic implications, as in SMN2 and dystrophin. It would also allow screening of libraries to identify potentially toxic chemicals that might inhibit or induce aberrant patterns of splicing.
